Review
doi: 10.1016/j.cimid.2007.07.011.
Epub 2007 Sep 21.
Towards a dengue vaccine: progress to date and remaining challenges
Affiliations
- PMID: 17889365
- DOI: 10.1016/j.cimid.2007.07.011
Item in Clipboard
Review
Towards a dengue vaccine: progress to date and remaining challenges
Comp Immunol Microbiol Infect Dis.
2008 Mar.
Abstract
The increased incidence and extended geographical reach of Dengue virus over the past two decades have made the development of an effective vaccine an international urgency. Various strategies are being pursued, including live, vectored and killed/recombinant preparations. For all approaches, the challenge is to induce a broad durable immune response against all four serotypes of Dengue virus simultaneously whilst avoiding the possible exacerbation of risk of developing the severe forms of disease through incomplete or modified responses. This review presents the current state of knowledge and discusses the challenges of further clinical development.
Similar articles
-
Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.Vaccine. 2009 Oct 30;27(46):6444-53. doi: 10.1016/j.vaccine.2009.06.061. Epub 2009 Jul 4. Vaccine. 2009. PMID: 19580892
-
An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.Vaccine. 2009 Oct 9;27(43):6011-21. doi: 10.1016/j.vaccine.2009.07.073. Epub 2009 Aug 7. Vaccine. 2009. PMID: 19665609
-
Efficacy of a live attenuated tetravalent candidate dengue vaccine in naïve and previously infected cynomolgus macaques.Vaccine. 2007 Jul 20;25(29):5409-16. doi: 10.1016/j.vaccine.2007.04.079. Epub 2007 May 21. Vaccine. 2007. PMID: 17560694
-
Review of dengue virus and the development of a vaccine.Biotechnol Adv. 2011 Mar-Apr;29(2):239-47. doi: 10.1016/j.biotechadv.2010.11.008. Epub 2010 Dec 10. Biotechnol Adv. 2011. PMID: 21146601 Review.
-
Dengue vaccine: opportunities and challenges.IDrugs. 2008 Jan;11(1):42-5. IDrugs. 2008. PMID: 18175262 Review.
Cited by
-
Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.Hum Vaccin Immunother. 2013 Nov;9(11):2317-25. doi: 10.4161/hv.25562. Epub 2013 Jul 9. Hum Vaccin Immunother. 2013. PMID: 23839107 Free PMC article. Clinical Trial.
-
Epidemics with multistrain interactions: the interplay between cross immunity and antibody-dependent enhancement.Chaos. 2009 Dec;19(4):043123. doi: 10.1063/1.3270261. Chaos. 2009. PMID: 20059219 Free PMC article.
-
Flavitrack analysis of the structure and function of West Nile non-structural proteins.Int J Bioinform Res Appl. 2010;6(2):134-46. doi: 10.1504/IJBRA.2010.032117. Int J Bioinform Res Appl. 2010. PMID: 20223736 Free PMC article.
-
Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2.Immune Netw. 2011 Oct;11(5):268-80. doi: 10.4110/in.2011.11.5.268. Epub 2011 Oct 31. Immune Netw. 2011. PMID: 22194710 Free PMC article.
-
The Development of Peptide-based Antimicrobial Agents against Dengue Virus.Curr Protein Pept Sci. 2018;19(10):998-1010. doi: 10.2174/1389203719666180531122724. Curr Protein Pept Sci. 2018. PMID: 29852867 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
